CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
CRISPR Therapeutics to Participate Upcoming Investor Conferences
CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference
CRISPR Therapeutics and Vertex Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
View All Press
CRISPR Therapeutics Corporate Presentation
Innovation Day Presentation
EHA 2022 (Exa-cel)
2022 EHA Oral Presentation (CTX130 COLBALT-LYM)
View All Presentations
CRISPR Therapeutics is not responsible for the content or availability of third-party sites.
Continue